Envoy Medical, Inc. 8K

Envoy Medical reported Q2 2026 results, key regulatory and clinical milestones for its Acclaim cochlear implant, expanded patents, and terminated its $15 million ATM equity program while maintaining a strengthened cash position despite ongoing losses.

Envoy Medical Inc. filed a Form 8-K to furnish a press release announcing its second quarter 2026 financial results and business update, highlighting the submission of the first module of its modular Premarket Approval (PMA) application to the FDA for its Breakthrough Device-designated investigational fully implanted Acclaim cochlear implant, the achievement of key clinical milestones including positive 12‑month Stage 1 speech perception data and completion of the three‑month follow‑up window for the full pivotal trial cohort, expansion of its intellectual property portfolio through four new Australian and European patents, and the termination of its $15 million at-the-market equity facility, along with reporting a Q2 2026 net loss attributable to common stockholders of $7.3 million on minimal revenues and an improved cash balance of approximately $19.7 million as of June 30, 2026 following a significant equity raise earlier in the year.

Filing Facts

CIK

1840877

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-087221

Alert Tier

6